Q32 Bio Inc. (QTTB) stock
QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.53−0.10 (-1.16%)
Close on Nov 18, 2026Market cap $253.93MP/E –Yield –
Q32 Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Q32 Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$19.83M. For fiscal 2025 it was -$33.54M. The highest annual figure on record is $6.48M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$33.54M | – |
| FY2024 | Dec 31, 2024 | -$67.72M | – |
| FY2023 | Dec 31, 2023 | -$18.68M | – |
| FY2022 | Dec 31, 2022 | -$113.66M | – |
| FY2021 | Dec 31, 2021 | -$109.75M | – |
| FY2020 | Dec 31, 2020 | -$94.33M | – |
| FY2019 | Dec 31, 2019 | -$91.36M | – |
| FY2018 | Dec 31, 2018 | -$42.56M | -756.9% |
| FY2017 | Dec 31, 2017 | $6.48M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.18M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.23M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.48M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.52M | -222.8% |
| Q2 FY2024 | Jun 30, 2024 | -$22.21M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.55M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.72M | – |
| Q3 FY2023 | Sep 30, 2023 | $15.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.20M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.93M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$30.68M | – |
| Q4 FY2021 | Dec 31, 2021 | -$30.43M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.39M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.11M | – |
| Q1 FY2021 | Mar 31, 2021 | -$29.82M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.61M | – |
| Q3 FY2020 | Sep 30, 2020 | -$28.89M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.99M | – |
| Q1 FY2020 | Mar 31, 2020 | -$25.85M | – |
| Q4 FY2019 | Dec 31, 2019 | -$26.33M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.48M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.67M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.87M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.08M | -136.6% |
| Q3 FY2018 | Sep 30, 2018 | -$13.69M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.75M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.04M | – |
| Q4 FY2017 | Dec 31, 2017 | $22.05M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.45M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.60M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.52M | – |
See a number that looks wrong?